Humoral immunity against SARS-CoV-2 evoked by heterologous vaccination groups using the CoronaVac (Sinovac) and BNT162b2 (Pfizer/BioNTech) vaccines in Chile

Humoral immunity against SARS-CoV-2 evoked by heterologous vaccination groups using the CoronaVac (Sinovac) and BNT162b2 (Pfizer/BioNTech) vaccines in Chile

IntroductionSevere acute respiratory syndrome virus 2 (SARS-CoV-2) has caused over million deaths worldwide, with more than 61,000 deaths in Chile. The Chilean government has implemented a vaccination program against SARS-CoV-2, with over 17.7 million people receiving a complete vaccination scheme....

Full description

Bibliographic Details
Main Authors: Diego A. Díaz-Dinamarca, Pablo Díaz, Gisselle Barra, Rodrigo Puentes, Loredana Arata, Jonnathan Grossolli, Boris Riveros-Rodriguez, Luis Ardiles, Julio Santelises, Valeria Vasquez-Saez, Daniel F. Escobar, Daniel Soto, Cecilia Canales, Janepsy Díaz, Liliana Lamperti, Daniela Castillo, Mychel Urra, Felipe Zuñiga, Valeska Ormazabal, Estefanía Nova-Lamperti, Rosana Benítez, Alejandra Rivera, Claudia P. Cortes, María Teresa Valenzuela, Heriberto E. García-Escorza, Abel E. Vasquez
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-08-01
Series:Frontiers in Public Health
Subjects:
SARS-CoV-2
Chilean vaccination
SARS-CoV-2 neutralizing antibodies
COVID19
BNT162b2 (Pfizer-BioNTech)
CoronaVac vaccine
Online Access:https://www.frontiersin.org/articles/10.3389/fpubh.2023.1229045/full

Internet

https://www.frontiersin.org/articles/10.3389/fpubh.2023.1229045/full

Similar Items